Literature DB >> 17576971

Progressive licensing needs progressive open debate.

Paul C Hébert, Matthew Stanbrook, Barbara Sibbald, Ken Flegel, Noni MacDonald, Amir Attaran.   

Abstract

Mesh:

Year:  2007        PMID: 17576971      PMCID: PMC1891144          DOI: 10.1503/cmaj.070703

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  4 in total

1.  Health Canada's Progressive Licensing Framework.

Authors:  Neil Yeates; David K Lee; Maurica Maher
Journal:  CMAJ       Date:  2007-06-19       Impact factor: 8.262

2.  Progressive drug licensing: an opportunity to achieve transparency and accountability?

Authors:  James M Wright
Journal:  CMAJ       Date:  2007-06-19       Impact factor: 8.262

3.  Health Canada proposes new regulatory regime for drugs.

Authors:  Wayne Kondro
Journal:  CMAJ       Date:  2007-04-24       Impact factor: 8.262

4.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

Authors:  Steven E Nissen; Kathy Wolski
Journal:  N Engl J Med       Date:  2007-05-21       Impact factor: 91.245

  4 in total
  1 in total

Review 1.  Product regulation and the clinical translation of stem cell research.

Authors:  Barbara von Tigerstrom
Journal:  Stem Cell Rev Rep       Date:  2009-03-04       Impact factor: 5.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.